The combined treatment of anti-IL-6R with anti-programmed death-ligand 1 (PD-L1) immunotherapy can decrease tumor growth, reduce the abundance of α-smooth muscle actin (α-SMA) + fibroblasts and increase the infiltration of effector T-cells (25). Here, ACTA1 is linked to neoplasm.